

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

NYMOX PHARMACEUTICAL CORP  
Form 6-K  
October 22, 2003

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the month of October, 2003

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

9900 Cavendish Blvd., St. Laurent, QC, Canada, H4M 2V2

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F   
-----

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No   
-----

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

82-\_\_\_\_\_

On October 3, 2003, The Company filed an action against certain private investors in the company, their agents, and others in the United States District Court of the Southern District of New York. (Nymox Pharmaceutical Corp. v. Rhino Advisors, Inc. et al., 03-CV-7844 (MGC)). The complaint alleges that the defendants, inter alia, violated federal securities laws, breached their contractual commitments, and/or breached their fiduciary duties toward Nymox in connection with 2 financing agreements in 1999 and 2000.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION  
(Registrant)

By: /s/ Paul Averback

-----  
Paul Averback  
President and Chief Executive Officer

Date: October 21, 2003

3